Oncoustics, a Toronto-based medtech startup that develops advanced AI solutions for low-cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need, has been awarded the INOVAIT Focus Fund to advance its suite of AI-driven tissue characterization solutions. The resulting products may significantly improve patient outcomes and reduce the overall cost of healthcare by providing easier access to screening, diagnostics and monitoring for earlier interventions, as well as improved treatments for all patients with or at risk of asymptomatic structural liver disease.

Oncoustics is an OBIO® member, alumnus of our BDSP™, CAAP® and EAHN™ programs, and presented at the OBIO® Investment Summit.